American Diabetes Association Announces Statement on Compounded Incretin Products
December 03, 2024
December 03, 2024
INDIANAPOLIS, Indiana, Dec. 3 -- The American Diabetes Association issued the following statement on Dec. 2, 2024:
* * *
Today, the American Diabetes Association(R) (ADA) released a guidance statement on the use of compounded GLP-1 RA (glucagon-like peptide-1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 RA) medication classes. The statement recommends against using non-Food & Drug Administration (FDA)-approved compo . . .
* * *
Today, the American Diabetes Association(R) (ADA) released a guidance statement on the use of compounded GLP-1 RA (glucagon-like peptide-1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 RA) medication classes. The statement recommends against using non-Food & Drug Administration (FDA)-approved compo . . .